Altobelli Emma, Marzioni Daniela, Lattanzi Amedeo, Angeletti Paolo Matteo
Department of Life, Health and Environmental Sciences, Epidemiology and Biostatistics Unit, AUSL Teramo, University of L'Aquila, L'Aquila, Italy.
Department of Experimental and Clinical Medicine, University of Ancona, Ancona, Italy.
Oncol Rep. 2015 Aug;34(2):555-66. doi: 10.3892/or.2015.4016. Epub 2015 May 28.
HtrA1 appears to be involved in several physiological processes as well as in the pathogenesis of conditions such as Alzheimer's disease and osteoarthritis. It has also been hypothesized to play a role as a tumor suppressor. This manuscript reviews the current cancer-related HtrA1 research from the methodological and clinical standpoints including studies regarding its potential role as a tumor marker and/or prognostic factor. PRISMA method was used for study selection. The articles thus collected were examined and selected by two independent reviewers; any disagreement was resolved by a methodologist. A laboratory researcher reviewed the methods and laboratory techniques. Fifteen studies met the inclusion criteria and concerned the following cancer sites: the nervous system, bladder, breast, esophagus, stomach, liver, endometrium, thyroid, ovaries, pleura, lung and skin. Most articles described in vivo studies using a morphological approach and immunohistochemistry, whereas protein expression was quantified as staining intensity scored by two raters. Often the results were not comparable due to the different rating scales and study design. Current research on HtrA1 does not conclusively support its role as a tumor suppressor.
HtrA1似乎参与了多种生理过程以及诸如阿尔茨海默病和骨关节炎等病症的发病机制。也有人假设它具有肿瘤抑制作用。本手稿从方法学和临床角度综述了当前与癌症相关的HtrA1研究，包括关于其作为肿瘤标志物和/或预后因素的潜在作用的研究。采用PRISMA方法进行研究选择。收集到的文章由两位独立评审员进行审查和筛选；如有分歧，由一位方法学家解决。一位实验室研究人员审查了方法和实验室技术。15项研究符合纳入标准，涉及以下癌症部位：神经系统、膀胱、乳腺、食管、胃、肝脏、子宫内膜、甲状腺、卵巢、胸膜、肺和皮肤。大多数文章描述了使用形态学方法和免疫组织化学的体内研究，而蛋白质表达则通过两位评分者对染色强度进行量化。由于评分标准和研究设计不同，结果往往不可比。目前关于HtrA1的研究并未确凿支持其作为肿瘤抑制因子的作用。
